Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
In the National Comprehensive Cancer Network (NCCN) guideline for NSCLC, epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is recommended as the third-line
treatment for EGFR gene mutation negative NSCLC patients who failed to the first-line
platinum doublet chemotherapy [i.e. paclitaxel-carboplatin (PC) or gemcitabine-cisplatin
(GP)] and the second-line chemotherapy with docetaxel or pemetrexed. But as we know, if
patients had no EGFR gene mutation, EGFR-TKI treatment is not effective. The overall survival
is short and the objective response rate is low. As for EGFR gene wild type patients with
good performance status, besides EGFR-TKI treatment, other first generation cytotoxic drugs
i.e. vinorelbine or ifosfamide maybe an alternative treatment. So the purpose of this
clinical trial is to compare the effectiveness and safety of vinorelbine-ifosfamide with
gefitinib in advanced or metastatic EGFR gene mutation negative NSCLC patients.